読み込み中
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
前日終値
$1.60
+$0.12 · +8.11%
日中の時刻はETです。市場データは遅延する場合があります。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日中レンジ
現在 $1.60
52週レンジ
現在 $1.60
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
53
適正価値
センチメント
60
まちまち
リスク
62
高リスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
日中レンジ
現在 $1.60
52週レンジ
現在 $1.60
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 91.7万 USD | 63.7万 USD | 27.9万 USD | 41万 USD | 80.2万 USD |
| 売上原価 | 42.2万 USD | 15.4万 USD | — | — | 7万 USD |
| 粗利益 | 49.5万 USD | 48.3万 USD | 27.9万 USD | 41万 USD | 80.2万 USD |
| 研究開発 | 1282.3万 USD | 9403.1万 USD | 631.2万 USD | 874.2万 USD | 490.7万 USD |
| 販売・一般管理 | 1378.1万 USD | 885.4万 USD | 893.2万 USD | 1697.8万 USD | 2041.6万 USD |
| 営業費用 | 2660.4万 USD | 1.03億 USD | 1532.2万 USD | 6088.7万 USD | 2900.1万 USD |
| 受取利息 | 199.6万 USD | 238.3万 USD | 325.3万 USD | 20.1万 USD | 2000 USD |
| 支払利息 | 65.8万 USD | 24.8万 USD | — | 6000 USD | 1.2万 USD |
| 減価償却費と償却費 | 28.8万 USD | 22.5万 USD | 7.8万 USD | 7.2万 USD | 7万 USD |
| 営業利益 | −2610.9万 USD | −1.03億 USD | −1504.3万 USD | −6047.7万 USD | −2119.9万 USD |
| 純利益 | −3052万 USD | −3441万 USD | −187.6万 USD | −1.25億 USD | −2454.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2009年12月18日 | $0.02Semi-Annual | — | 2009年12月31日 |
配当 | 2009年6月19日 | $0.02Semi-Annual | — | 2009年6月30日 |
配当落ち 2009年12月18日
$0.02
Semi-Annual
支払日 2009年12月31日
配当落ち 2009年6月19日
$0.02
Semi-Annual
支払日 2009年6月30日
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI250.74万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF121.93万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC15.47万0.01%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC13.72万0.00%75.58億 USD0.43%$57.813+0.20%
Dimensional - US Small Cap ETFDFAS6.63万0.00%338.69億 USD0.31%$78.35+0.32%
Dimensional - US Core Equity 2 ETFDFAC5.39万0.00%885.96億 USD0.21%$45.33+0.49%
U.S. Vector Equity Portfolio ETF Class SharesDXUV3.55万0.00%61.81億 USD0.26%$68.28+0.25%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR2.92万0.00%455.91億 USD0.17%$84.44+0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Core Equity 2 ETFDFACU.S. Vector Equity Portfolio ETF Class SharesDXUVU.S. Core Equity 1 Portfolio ETF Class SharesDCORAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
